SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories reports 70% fall in Q3 net profit

09 Feb 2015 Evaluate

Ipca Laboratories has reported results for third quarter ended December 31, 2014.

The company has reported 70.15% fall in its net profit at Rs 41.53 crore for the quarter under review as compared to of Rs 139.12 crore for the same quarter in the previous year. Total income of the company has decreased 10.89% at Rs 747.09 crore for Q3FY15 as compared Rs 838.37 crore for the corresponding quarter previous year.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

 

Ipca Laboratories Share Price

1550.60 6.65 (0.43%)
06-May-2026 09:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1833.00
Dr. Reddys Lab 1282.80
Cipla 1340.00
Zydus Lifesciences 920.80
Lupin 2384.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×